Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Alexza wins funding from private investor
December 11, 2006
| A version of this story appeared in
Volume 84, Issue 50
Alexza Pharmaceuticals has received $50 million from private equity firm Symphony Capital Partners to support the development of two drugs for the psychiatric market. AZ-002, for panic attacks, and AZ-004, for agitation in schizophrenia patients, are both in Phase IIa clinical trials. Alexza says the cash will facilitate its goal of bringing the drugs to market on its own. Alexza has granted the private equity firm a license to the intellectual property related to the two drugs, but Alexza retains the option to buy it back at a set price during the next four years.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter